Revolution Medicines, Inc. (RVMD) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | (m) | $742.00K | (m) | (m) |
| 2024-06-30 | (m) | $742.00K | (m) | (m) |
| 2024-03-31 | (m) | $4.57M | (m) | (m) |
| 2023-12-31 | (m) | $11.58M | (m) | (m) |
| 2023-09-30 | (m) | $26.17M | (m) | (m) |
| 2023-06-30 | (m) | $29.52M | (m) | (m) |
| 2023-03-31 | (m) | $34.82M | (m) | (m) |
| 2022-12-31 | (m) | $35.38M | (m) | (m) |
| 2022-09-30 | (m) | $29.51M | (m) | (m) |
| 2022-06-30 | (m) | $27.25M | (m) | (m) |
| 2022-03-31 | (m) | $26.84M | (m) | (m) |
| 2021-12-31 | (m) | $29.39M | (m) | (m) |
| 2021-09-30 | (m) | $28.68M | (m) | (m) |
| 2021-06-30 | (m) | $40.24M | (m) | (m) |
| 2021-03-31 | (m) | $41.57M | (m) | (m) |
| 2020-12-31 | (m) | $42.98M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $50.04M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $20.16M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |